Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
B010-A
i
Other names:
B010-A
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Shanghai Pharma
Drug class:
GPC-3-targeted CAR-T immunotherapy
Related drugs:
‹
CT017 (1)
ADI-002 (0)
AGAR T cells (0)
AZD7003 (0)
BOXR1030 (0)
CT011 (0)
CT0180 (0)
CT0181 (0)
EU307 (0)
GAP T cells (0)
GLYCAR T cells (0)
GPC3-CAR and IL15 plus IL21 (0)
GPC3-CAR-T Cells (0)
GPC3-CAR-T cells (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
IM83 (0)
LB2101 (0)
Mesothelin/GPC3/GUCY2C-CAR-T (0)
NIB102 (0)
Ori-C101 (0)
TAI-GPC3-CART cells (0)
CT017 (1)
ADI-002 (0)
AGAR T cells (0)
AZD7003 (0)
BOXR1030 (0)
CT011 (0)
CT0180 (0)
CT0181 (0)
EU307 (0)
GAP T cells (0)
GLYCAR T cells (0)
GPC3-CAR and IL15 plus IL21 (0)
GPC3-CAR-T Cells (0)
GPC3-CAR-T cells (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
IM83 (0)
LB2101 (0)
Mesothelin/GPC3/GUCY2C-CAR-T (0)
NIB102 (0)
Ori-C101 (0)
TAI-GPC3-CART cells (0)
›
Associations
News
Trials
Filter by
Latest
11ms
B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=3, Active, not recruiting, Tongji University | Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Sep 2024 | Trial primary completion date: Aug 2022 --> Aug 2024
11 months ago
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
GPC3 (Glypican 3)
|
GPC3 positive
|
B010-A
over2years
B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=3, Recruiting, Tongji University | Trial primary completion date: May 2022 --> Aug 2022
over 2 years ago
Trial primary completion date
|
GPC3 (Glypican 3) • CRP (C-reactive protein)
|
GPC3 positive
|
B010-A
almost3years
B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=3, Recruiting, Tongji University | Initiation date: Jul 2021 --> Oct 2021
almost 3 years ago
Trial initiation date
|
GPC3 (Glypican 3) • CRP (C-reactive protein)
|
GPC3 positive
|
B010-A
3years
B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=3, Recruiting, Tongji University
3 years ago
Clinical • New P1 trial
|
GPC3 (Glypican 3) • CRP (C-reactive protein)
|
GPC3 positive
|
B010-A
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login